AdAlta is pleased to share with you our June 2018 Shareholder Update. AdAlta has already had a very exciting 2018; announcing its second generation lead candidate, AD-214, as well as its manufacturing partners to take AD-214 through preclinical development and into the clinic in 2020.
AdAlta is looking forward to progressing AD-214 with improved therapeutic and commercial potential, if you would like to keep up to date with progress, sign up to be an AdAlta subscriber here.